Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial

PLoS Medicine

Volumn 11, Issue 12, 2014, Pages

  Qu, Chunfeng ^a   Chen, Taoyang ^b   Fan, Chunsun ^b   Zhan, Qimin ^a   Wang, Yuting ^a   Lu, Jianhua ^b   Lu, Ling ling ^b   Ni, Zhengping ^b   Huang, Fei ^b   Yao, Hongyu ^b   Zhu, Jian ^b   Fan, Jian ^b   Zhu, Yuanrong ^b   Wu, Zhiyuan ^a   Liu, Guoting ^a   Gao, Wenhong ^a   Zang, Mengya ^a   Wang, Dongmei ^a   Dai, Min ^a   Hsia, Chu Chieh ^a   Zhang, Yawei ^a,b,c   Sun, Zongtang ^a   more..

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b QIDONG LIVER CANCER INSTITUTE   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; END STAGE LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; INTERVENTION STUDY; LIVER CANCER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SEROPREVALENCE; VACCINATION; CHINA; HEPATITIS B; IMMUNOLOGY; LIVER DISEASES; LIVER NEOPLASMS; NEWBORN; PATHOGENICITY; STATISTICS AND NUMERICAL DATA;

CHINA; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INFANT, NEWBORN; LIVER DISEASES; LIVER NEOPLASMS; VACCINATION;

EID: 84920989573     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001774     Document Type: Article

References (50)

1. Hyams KC, (1995) Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 20: 992–1000.
2. Chang MH, (2007) Hepatitis B virus infection. Semin Fetal Neonatal Med 12: 160–167.
3. Finelli L, Bell BP (2011) Chapter 4: Hepatitis B. VPD survellance manual, 5th edition: 4-1-13.
4. Chang MH, Lee CY, Chen DS, Hsu HC, Lai MY, (1987) Fulminant hepatitis in children in Taiwan: the important role of hepatitis B virus. J Pediatr 111: 34–39.
5. McMahon BJ, (2009) The natural history of chronic hepatitis B virus infection. Hepatology 49: S45–55.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
7. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, et al. (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10: 1111–1118.
8. Chen DS, (2009) Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 50: 805–816.
9. Zanetti AR, Van Damme P, Shouval D, (2008) The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26: 6266–6273.
10. Zuckerman AJ, Sun TT, Linsell A, Stjernsward J, (1983) Prevention of primary liver cancer-report on a meeting of a W.H.O. Scientific Group. Lancet 1: 463–465.
11. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, et al. (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101: 1348–1355.
12. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ, (2013) Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 310: 974–976.
13. Chien YC, Jan CF, Chiang CJ, Kuo HS, You SL, et al. (2014) Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees. Hepatology 60: 125–132.
14. McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, et al. (2011) Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 54: 801–807.
15. Gwack J, Park SK, Lee EH, Park B, Choi Y, et al. (2011) Hepatitis B vaccination and liver cancer mortality reduction in Korean children and adolescents. Asian Pac J Cancer Prev 12: 2205–2208.
16. Wu QJ, Vogtmann E, Zhang W, Xie L, Yang WS, et al. (2012) Cancer incidence among adolescents and young adults in urban Shanghai, 1973-2005. PLoS One 7: e42607.
17. Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, et al. (2013) Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 34: 1800–1805.
18. Chen JG, Kensler TW, (2013) Changing rates for liver and lung cancer in Qidong, China. Chem Res Toxicol 27: 3–6.
19. Chen JG, Zhu J, Parkin DM, Zhang YH, Lu JH, et al. (2006) Trends in the incidence of cancer in Qidong, China, 1978-2002. Int J Cancer 119: 1447–1454.
20. Gao J, Xie L, Chen WQ, Zhang SW, Wu QJ, et al. (2013) Rural-urban, sex variations, and time trend of primary liver cancer incidence in China, 1988-2005. Eur J Cancer Prev 22: 448–454.
21. Sun Z, Ming L, Zhu X, Lu J, (2002) Prevention and control of hepatitis B in China. J Med Virol 67: 447–450.
22. Sun Z, Zhu Y, Stjernsward J, Hilleman M, Collins R, et al. (1991) Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detect Prev 15: 313–318.
23. Chen JG (2013) Qidong Cancer Registration System Cancer Cancer in Qidong, China. Chen JG, editor. Beijing: Military Medical Science Press. pp9-23.
24. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer incidence in five continents, vol. VIII. Sci Publ number 155. Lyon: IARC. pp 212–231.
25. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, et al. (2009) Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 3: 269–282.
26. Wu M, Shen F (2010) Liver cancer. 3rd edition. Beijing: Peking University Medical Press pp.327.
27. Wiwanitkit V, (2005) Hepatitis virus B is not a risk factor in hepatoblastoma patients. Asian Pac J Cancer Prev 6: 213–214.
28. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, et al. (2000) Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 284: 3040–3042.
29. Kensler TW, Qian GS, Chen JG, Groopman JD, (2003) Translational strategies for cancer prevention in liver. Nat Rev Cancer 3: 321–329.
30. Xia GL, Liu CB, Cao HL, Bi SL, Zhan MY, et al. (1996) Prevalence of hepatitis B and C virus infections in the general Chinese population: results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B,C, D and E virus infections in China, 1992. Int Hepatol Commun 5: 12.
31. Zhang HW, Yin JH, Li YT, Li CZ, Ren H, et al. (2008) Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 57: 1713–1720.
32. Hutton DW, So SK, Brandeau ML, (2010) Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 51: 405–414.
33. Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, et al. (2000) Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 181: 413–418.
34. Chu CM, Liaw YF, (2007) HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 45: 1187–1192.
35. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, et al. (2010) Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 139: 474–482.
36. Yalcin K, Acar M, Degertekin H, (2003) Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 31: 221–225.
37. Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, et al. (2004) Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 40: 1415–1420.
38. Zhu CL, Liu P, Chen T, Ni Z, Lu LL, et al. (2011) Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine 29: 7835–7841.
39. Romano L, Carsetti R, Tozzi AE, Mele A, Zanetti AR, (2014) Chronic hepatitis B infection in adolescents vaccinated at birth: an alarm bell in favor of the need for a booster? Hepatology 59: 349.
40. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, et al. (2007) Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 132: 1287–1293.
41. Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, et al. (2013) Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 59: 24–30.
42. Lu L, Chen B, Wang J, Wang D, Ji Y, et al. (2014) Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women. Int J Infect Dis 28: 41–4.
43. Lu FM, Zhuang H, (2009) Management of hepatitis B in China. Chin Med J (Engl) 122: 3–4.
44. Beath SV, Boxall EH, Watson RM, Tarlow MJ, Kelly DA, (1992) Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers. BMJ 304: 1169–1170.
45. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, et al. (1999) Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 30: 379–383.
46. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, et al. (2002) Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36: 1214–1220.
47. Chuang SC, La Vecchia C, Boffetta P, (2009) Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 286: 9–14.
48. Mast EE, Mahoney FJ, Alter MJ, Margolis HS, (1998) Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine 16 Suppl: S48-51
49. Ramachandran S, Purdy MA, Xia GL, Campo DS, Dimitrova ZE, et al. (2014) Recent population expansions of hepatitis B virus in the United States. J Virol. In press.
50. Arevalo JA, Washington AE, (1988) Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA 259: 365–369.